New stock news | Junqi Holdings Limited submitted an application to the Hong Kong Stock Exchange. In 2025, the company has a 12.8% market share of the Chinese beauty service platform in Taiwan.

According to the disclosure made by the Hong Kong Stock Exchange on April 30, 2026, Junqi Holdings Limited has submitted an application for listing to the Hong Kong Stock Exchange, with Guotai Haitong as the exclusive sponsor. Company Overview Based on information from Frost & Sullivan, Junqi Holdings Limited is a major player in the Chinese Taiwan women's health services market. The company operates under the flagship brand "Junqi" and adopts a brand-driven business-to-business-to-consumer (B-to-B-to-C) cooperation model, providing comprehensive non-medical operational support services to medical beauty clinics operated by licensed physicians. In 2024, the company strategically expanded into the field of traditional Chinese medicine, further expanding its business layout in the women's health consumer market. With its integrated capabilities in brand management and member data management, combined with AI-driven data analysis technology, the company is able to effectively explore and maximize the value of members in multiple dimensions of health and wellness, covering but not limited to medical beauty, anti-aging, skin and body rejuvenation, and traditional Chinese medicine. Junqi Holdings Limited is currently focused on operations in Chinese Taiwan while actively exploring opportunities to expand into the Japanese market. According to Frost & Sullivan data, based on 2025 revenue, the company is one of the largest medical beauty service brands in Chinese Taiwan, and based on 2025 revenue, one of the largest beauty service platforms in Chinese Taiwan, accounting for approximately 12.8% of the total market share in the Chinese Taiwan beauty service platform industry in 2025. As of December 31, 2025, the company's flagship brand operates 19 clinics strategically located in major metropolitan areas of Chinese Taiwan, including Taipei, Taoyuan, Hsinchu, Taichung, and Kaohsiung. By December 31, 2025, the clinics had attracted a large loyal community of over 500,000 members, providing a stable and recurring source of income for the business. As of December 31, 2025, the clinics had served over 350,000 members, with over 90,000 active members in 2025. Data-driven management provides further support for the company's excellent operations. Through CRM systems and AI data analysis, the company can accurately grasp consumer behavior and preferences, design targeted marketing activities, provide customized treatment recommendations, and optimize the effectiveness of advertising through digital channels. In addition, through the integration of CRM, CTI, and LINE OA systems, with comprehensive post-treatment care and systematized interactions, the company continues to maintain long-term loyalty and repeat consumption among members. Financial Information Revenue In the financial years 2023, 2024, and 2025, the company's revenue was approximately HK$234 million, HK$387 million, and HK$634 million respectively. Gross Profit In the financial years 2023, 2024, and 2025, the company's gross profit was HK$19.73 million, HK$99.45 million, and HK$179 million respectively. Net Profit In the financial years 2023, 2024, and 2025, the company's net profits were HK$5.697 million, HK$71.28 million, and HK$149 million respectively. Industry Overview As disposable income increases and beauty consciousness rises, the Asian medical beauty services industry has experienced steady growth. In 2025, the industry growth temporarily slowed down, with stricter regulatory requirements and increased competition causing small enterprises to exit the market, leading to a reduction in supply. The industry has transitioned from a phase of rapid expansion to a more standardized development stage. By revenue, the market size of the Asian medical beauty services industry reached USD 49.1 billion in 2025. With the industry's regulation becoming more mature, new growth stages are expected. It is projected that from 2026 to 2030, the market size of the Asian medical beauty services industry will grow at a compound annual growth rate of 11.9%. The relatively well-established medical beauty system and high accessibility of medical beauty services in Chinese Taiwan provide a solid foundation for the widespread popularity of medical beauty services. With steady increases in residents' income levels and the gradual refinement of aesthetic preferences, medical beauty consumption is increasingly shifting towards daily care, driving continued market expansion. Particularly in the non-surgical field, such treatments are rapidly gaining popularity among young consumer groups and entry-level consumer groups due to their high safety, short recovery time, and relatively affordable prices. Furthermore, consumers' relatively high frequency of repeat consumption further promotes the continued expansion of the market. By revenue, the market size of the medical beauty services industry in Chinese Taiwan reached USD 2.4 billion in 2025. Looking ahead, the Chinese Taiwan medical beauty services industry is expected to enter a new growth stage centered on quality improvement. Against the backdrop of a relatively mature regulatory environment and ongoing improvement in medical beauty service standards, the market is expected to further expand. Additionally, consumption patterns are expected to gradually shift from single treatment consumption to long-term management and comprehensive solution models. It is projected that from 2026 to 2030, the Chinese Taiwan medical beauty services industry will grow at a compound annual growth rate of 14.2%. Board of Directors Information The board of directors currently consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors. Equity Structure Ms. Zhu holds approximately 99.93% equity in Ravix Holdings, Mr. Wang holds approximately 0.02% equity, and Mr. Zou holds approximately 0.05% equity. As of the latest practicable date, these independent third parties do not hold 5% or more of the company's shares. In addition, to support the company's business strategy of entering the Japanese medical beauty market, a subsidiary company, Junqi Japan, was established in Japan in February 2026. Intermediary Team Exclusive Sponsor: Guotai Junan Financing Limited Company Legal Advisor: Hong Kong law-related: A near law firm; Taiwanese law-related: Baker McKenzie International Law Firm; Cayman Islands law-related: Condoming Law Firm Exclusive Sponsor Legal Advisor: Hong Kong law-related: King & Wood law firm; Taiwanese law-related: Law Law Law Firm Auditors and Reporting Accountants: Deloitte Haohuang Chenfang Accountants Industry Consultants: Frost & Sullivan (Beijing) Consulting Co., Ltd. Shanghai Branch Compliance Advisor: Guotai Junan Financing Limited Property Valuers: Jones Lang LaSalle (JLL) Corporate Valuation and Consulting Limited